Novo Nordisk has ended its partnership with Hims & Hers Health Inc., citing “deceptive marketing” and the selling of ...

Harbour BioMed has partnered with Otsuka Pharmaceutical Co., Ltd. to advance BCMAxCD3 bispecific T-cell engagers for the ...

Cellular Origins has entered into a collaboration with Johnson & Johnson to develop a scalable, end-to-end automated platform ...

Celltrion UK has officially opened its new UK headquarters at the Charter Building in Uxbridge, UK. The opening ceremony was ...

PharmaLogic Holdings Corp., a CDMO, has completed its previously announced acquisition of a majority stake in Agilera Pharma.

Aversa Fentanyl combines Nutriband’s Aversa abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch.

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

How can early decisions in cell and gene therapy clinical development impact downstream progress toward commercialization and ...

Anne Wojcicki, co-founder and former CEO of 23andMe, is set to regain control of the DNA-testing company after a nonprofit ...

Will support spray drying and unit operations including granulation, encapsulation, compression and coating for oral dosage ...

This will support the advancement of a novel ophthalmic therapeutic through clinical development and onto the market.

They aim to transform output and labor requirements for CGT manufacturing using automated robotics manufacturing capabilities ...